dr fayyaz chaudhri
DESCRIPTION
Dr Fayyaz Chaudhri. Maryport Health Services GPwSI. Solar (actinic) Keratosis. Background of solar elastosis multiple flat or thickened scaly or warty skin coloured or reddened lesions. cutaneous horn. www. dermnetnz.org. Treatment Options. Cryotherapy Curettage & cautery Excision - PowerPoint PPT PresentationTRANSCRIPT
Dr Fayyaz Chaudhri
• Maryport Health Services
• GPwSI
Solar (actinic) Keratosis
• Background of solar elastosis
• multiple flat or thickened
• scaly or warty
• skin coloured or reddened lesions.
• cutaneous horn
www. dermnetnz.org
Treatment Options• Cryotherapy
• Curettage & cautery
• Excision
• 5-Fluorouracil cream
• Imiquimod
• Photodynamic therapy
• Diclofenac gel
5-FU (efudix)
• useful when there are many lesions on the face.
• applied once or twice daily for two to four weeks.
• Expect inflammation - red, raw and uncomfortable.
• Good end results
5-fluorouracil is a structural analogue of Thymine and Uracil with the 5-methyl group being replaced by fluorine.
Its activity can be explained by two mechanism:
Thymine
F
5-fluorouracilUracil
5-Fluorouracil : Mechanism of Action
UK/EFU/12/0007
Ref : Goette DK, J Am Acad Dermatol 1981;4(6):633-649
i) Metabolite competition 5-FU competes with normal metabolites for access to enzyme active sites and is eventually incorporated
into the host cell RNA molecules. These become ineffective molecules for protein synthesis 1,2
ii) Enzyme inhibition The 5-FU metabolite (5F-deoxyuridine monophosphate)
blocks the essential enzyme thymidylate synthetase thus preventing DNA synthesis 1,2
5-Fluorouracil : Mechanism of Action
UK/EFU/12/0007
Ref : Goette DK, J Am Acad Dermatol 1981;4(6):633-649
F
5-FU
Ineffective mRNA
F
5-Fluorouracil : Mechanism of Action
Triplet does not code for an
amino acid t-RNA
UK/EFU/12/0007
DNA replicationMaking new copies for dividing cells
F
5-fluorouracil metabolite inhibits thymidylate
synthetase
x
Enzyme inhibition Reduced DNA production
5-Fluorouracil : Mechanism of Action
ii) Enzyme inhibition
UK/EFU/12/0007
2 weeks after Efudix treatment
Therapeutic response depends on severity of disease
• Phase 1 - early, mild inflammation transformed cells die by necrosis
leading to ....• Phase 2 - Severe inflammation
• Phase 3 – lesion destruction and macrophage clearance
• Phase 4 – Scabbing, new tissue production and healing process.
Ref: Litwin MS, Ryan RF Reed Ej et al. J Surg Oncol 1971;3:351-65
5-Fluorouracil : Mechanism of Action
UK/EFU/12/0007
Excessive reaction
Imiquimod
• immune response modifier
• 2-3 times weekly for 4-12 weeks.
• inflammatory reaction,
• results are variable, but generally excellent.
AK treated with IMIQUIMOD
4 WEEKS AFTER TREATMENT
Intraepidermal SCC – Bowens
scc